Autophagy modulation: a target for cancer treatment development Alison DuffyJackson LeAshkan Emadi Review Article 25 November 2014 Pages: 439 - 447
Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer Tatsuya MiyazakiMakoto SohdaHiroyuki Kuwano Original Article 28 December 2014 Pages: 449 - 455
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival Akiyoshi KasugaNaohiro OkanoJunji Furuse Original Article 30 December 2014 Pages: 457 - 464
Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo Yaping LiuXiaoyan ZhangYunxia Wu Original Article 01 January 2015 Pages: 465 - 474
Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer Ji-Youn HanSoo Hyun LeeHeung Tae Kim Original Article Open access 01 January 2015 Pages: 475 - 483
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study Jaime R. MerchanRui QinCharles Erlichman Original Article 03 January 2015 Pages: 485 - 493
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing Mina NikanjamClinton F. StewartEdmund V. Capparelli Original Article 04 January 2015 Pages: 495 - 503
Dosing algorithm revisit for busulfan following IV infusion Yanlin WangKazunobu KatoXiaofeng Wang Original Article 06 January 2015 Pages: 505 - 512
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer Kenzo SoejimaKatsuhiko NaokiTomoko Betsuyaku Original Article 07 January 2015 Pages: 513 - 519
Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease Hirotsugu KenmotsuTateaki NaitoToshiaki Takahashi Original Article 07 January 2015 Pages: 521 - 526
The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer Yoshiko KakuAyako TsuchiyaTomoyuki Nishizaki Original Article Open access 08 January 2015 Pages: 527 - 535
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine Edward M. NewmanRobert J. MorganJames H. Doroshow Original Article 08 January 2015 Pages: 537 - 546
Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial Zhiyu ChenWeijian GuoJin Li Original Article 09 January 2015 Pages: 547 - 557
Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice Priscilla F. C. JustinoLuis F. M. MeloPedro Marcos Gomes Soares Original Article 09 January 2015 Pages: 559 - 567
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer Kentaro YamazakiHiroyuki KuwanoNarikazu Boku Original Article 10 January 2015 Pages: 569 - 577
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients T. C. ChangH. S. ShiahL. T. Chen Original Article Open access 11 January 2015 Pages: 579 - 586
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer Yasushi SatoHiroyuki OhnumaJunji Kato Original Article 11 January 2015 Pages: 587 - 594
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma Shweta JoshiAlok R. SinghDonald L. Durden Original Article 13 January 2015 Pages: 595 - 608
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus Krisztina GéresiAttila MegyeriIlona Benkő Original Article 13 January 2015 Pages: 609 - 618
Effect of axitinib on the QT interval in healthy volunteers Ana Ruiz-GarciaBrett E. HoukMichael A. Tortorici Original Article 15 January 2015 Pages: 619 - 628
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma Sandra P. D’ AngeloMichelle R. MahoneyGary K. Schwartz Original Article 12 February 2015 Pages: 629 - 638
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer Dae Ro ChoiSang Nam YoonDae Young Zang Original Article 29 January 2015 Pages: 639 - 643
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer Ying LiuZhonghai RenFeng Wang Clinical Trial Report Open access 20 January 2015 Pages: 645 - 651
Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies R. SalmonJ. B. ReyV. Launay-Vacher Short Communication 31 January 2015 Pages: 653 - 655
Erratum to: Does saturable formation of gemcitabine triphosphate occur in patients? Lai-San ThamLing-Zhi WangNicholas H. G. Holford Erratum 15 January 2015 Pages: 657 - 657